Status:
COMPLETED
Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Chlamydia
Eligibility:
FEMALE
15-35 years
Brief Summary
This is an exploratory study in which the investigators will develop a way to identify the cell responses most strongly associated with protection against chlamydia infection. This study is not driven...
Detailed Description
With more than 90 million new cases annually, Chlamydia trachomatis is the most common sexually transmitted bacterial disease. Untreated endocervical C. trachomatis infections can cause pelvic inflamm...
Eligibility Criteria
Inclusion
- Women between 15-35 years of age at the time of enrollment onto this study. Minors between the ages of 1-17 will require parental consent to participate in the study.
- History of, in past 5 years, endocervical C. trachomatis infection (total of 20 women) or no history of endocervical C. trachomatis infection (total of 10 women).
Exclusion
- Pregnancy.
- Immunocompromised, by history (including but not limited to known HIV, cancer, autoimmune diseases).
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00970749
Start Date
December 1 2009
End Date
June 1 2010
Last Update
April 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, United States, 15213